Proposal of a Feasible Synthetic Route to Ormosianine A via Retrosynthetic Analysis
Journal of Youth Impact · 10.04.2026
DOI: 10.66245/jyi.v1.i2.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Youth Impact, online erschienen am 10.04.2026. Verfasst von Seungmin Oh.
Abstract (Originalsprache)
Ormosianine A, a novel quinolizidine alkaloid isolated from Ormosia yunnanensis, has demonstrated potential acetylcholinesterase (AChE) inhibitory activity, with a Half-Maximal Inhibitory Concentration (IC50) value of 1.55 μM, stronger than most Alzheimer's Disease (AD) drugs currently being used. Despite its therapeutic potential in the treatment of AD, the compound's natural extraction process is extremely inefficient, yielding only 6.0 milligrams of the compound from 8.0 kilograms of the plant. To address this limitation, this study promises a retrosynthetic route to Ormosianine A using commercially available starting materials. The retrosynthesis started with an oxidation level analysis, which is then followed by a number of disconnections and synthetic techniques, most notably the Stork-Danheiser method. Strategic choices like keeping an olefin and controlling proton acidity with protective groups increase the plausibility of the retrosynthesis route. While challenges such as the incorporation of nitrogen exist, processes like reductive amination offer viable solutions. Overall, this retrosynthetic plan lays out a practical foundation for the lab-scale synthesis of Ormosianine A.
Zitieren
APA
Oh, S. (2026). Proposal of a Feasible Synthetic Route to Ormosianine A via Retrosynthetic Analysis. Journal of Youth Impact. https://doi.org/10.66245/jyi.v1.i2.002
Vancouver
Oh S. Proposal of a Feasible Synthetic Route to Ormosianine A via Retrosynthetic Analysis. Journal of Youth Impact. 2026. doi:10.66245/jyi.v1.i2.002
BibTeX
@article{Oh2026,
author = {Oh, Seungmin},
title = {Proposal of a Feasible Synthetic Route to Ormosianine A via Retrosynthetic Analysis},
journal = {Journal of Youth Impact},
year = {2026},
doi = {10.66245/jyi.v1.i2.002}
}
EUVIMED